Ohlfest JR - Search Results

1

Immunotoxin targeting CD133(+) breast carcinoma cells.

Ohlfest JR, Zellmer DM, Panyam J, Swaminathan SK, Oh S, Waldron NN, Toma S, Vallera DA. Ohlfest JR, et al. Drug Deliv Transl Res. 2013 Apr;3(2):195-204. doi: 10.1007/s13346-012-0066-2. Drug Deliv Transl Res. 2013. PMID: 25787984

2

Identification and characterization of a novel scFv recognizing human and mouse CD133.

Swaminathan SK, Niu L, Waldron N, Kalscheuer S, Zellmer DM, Olin MR, Ohlfest JR, Vallera DA, Panyam J. Swaminathan SK, et al. Among authors: ohlfest jr. Drug Deliv Transl Res. 2013 Apr;3(2):143-51. doi: 10.1007/s13346-012-0099-6. Drug Deliv Transl Res. 2013. PMID: 25787982 Free PMC article.

3

Identification of a novel monoclonal antibody recognizing CD133.

Swaminathan SK, Olin MR, Forster CL, Cruz KS, Panyam J, Ohlfest JR. Swaminathan SK, et al. Among authors: ohlfest jr. J Immunol Methods. 2010 Sep 30;361(1-2):110-5. doi: 10.1016/j.jim.2010.07.007. Epub 2010 Jul 30. J Immunol Methods. 2010. PMID: 20674577

4

A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculature.

Tsai AK, Oh S, Chen H, Shu Y, Ohlfest JR, Vallera DA. Tsai AK, et al. Among authors: ohlfest jr. J Neurooncol. 2011 Jun;103(2):255-66. doi: 10.1007/s11060-010-0392-5. Epub 2010 Sep 10. J Neurooncol. 2011. PMID: 20830604 Free PMC article.

5

Evaluation of a bispecific biological drug designed to simultaneously target glioblastoma and its neovasculature in the brain.

Oh S, Tsai AK, Ohlfest JR, Panoskaltsis-Mortari A, Vallera DA. Oh S, et al. Among authors: ohlfest jr. J Neurosurg. 2011 Jun;114(6):1662-71. doi: 10.3171/2010.11.JNS101214. Epub 2011 Feb 4. J Neurosurg. 2011. PMID: 21294620

6

Targeting tumor-initiating cancer cells with dCD133KDEL shows impressive tumor reductions in a xenotransplant model of human head and neck cancer.

Waldron NN, Kaufman DS, Oh S, Inde Z, Hexum MK, Ohlfest JR, Vallera DA. Waldron NN, et al. Among authors: ohlfest jr. Mol Cancer Ther. 2011 Oct;10(10):1829-38. doi: 10.1158/1535-7163.MCT-11-0206. Epub 2011 Aug 23. Mol Cancer Ther. 2011. PMID: 21862685 Free PMC article.

7

CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer.

Swaminathan SK, Roger E, Toti U, Niu L, Ohlfest JR, Panyam J. Swaminathan SK, et al. Among authors: ohlfest jr. J Control Release. 2013 Nov 10;171(3):280-7. doi: 10.1016/j.jconrel.2013.07.014. Epub 2013 Jul 18. J Control Release. 2013. PMID: 23871962

8

Intracranial elimination of human glioblastoma brain tumors in nude rats using the bispecific ligand-directed toxin, DTEGF13 and convection enhanced delivery.

Oh S, Ohlfest JR, Todhunter DA, Vallera VD, Hall WA, Chen H, Vallera DA. Oh S, et al. Among authors: ohlfest jr. J Neurooncol. 2009 Dec;95(3):331-342. doi: 10.1007/s11060-009-9932-2. Epub 2009 Jun 11. J Neurooncol. 2009. PMID: 19517064

9

Profound impairment of adaptive immune responses by alkylating chemotherapy.

Litterman AJ, Zellmer DM, Grinnen KL, Hunt MA, Dudek AZ, Salazar AM, Ohlfest JR. Litterman AJ, et al. Among authors: ohlfest jr. J Immunol. 2013 Jun 15;190(12):6259-68. doi: 10.4049/jimmunol.1203539. Epub 2013 May 17. J Immunol. 2013. PMID: 23686484 Free PMC article.

10

Persistence of CD133+ cells in human and mouse glioma cell lines: detailed characterization of GL261 glioma cells with cancer stem cell-like properties.

Wu A, Oh S, Wiesner SM, Ericson K, Chen L, Hall WA, Champoux PE, Low WC, Ohlfest JR. Wu A, et al. Among authors: ohlfest jr. Stem Cells Dev. 2008 Feb;17(1):173-84. doi: 10.1089/scd.2007.0133. Stem Cells Dev. 2008. PMID: 18271701

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

64 results

Search Page